Английская Википедия:Bexagliflozin

Материал из Онлайн справочника
Версия от 23:08, 8 февраля 2024; EducationBot (обсуждение | вклад) (Новая страница: «{{Английская Википедия/Панель перехода}} {{Short description|Antidiabetic medication}} {{Use American English|date=December 2022}} {{Use dmy dates|date=December 2022}} {{cs1 config |name-list-style=vanc |display-authors=6}} {{Infobox drug | drug_name = | INN = | type = <!-- empty --> | image = Bexagliflozin structure.svg | width = 325 | alt = | captio...»)
(разн.) ← Предыдущая версия | Текущая версия (разн.) | Следующая версия → (разн.)
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Use American English Шаблон:Use dmy dates Шаблон:Cs1 config Шаблон:Infobox drug

Bexagliflozin, sold under the brand name Brenzavvy, is an antidiabetic medication used to improve glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise.[1] It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is taken by mouth.[2][3]

Medical uses

Bexagliflozin is indicated to improve glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise.[4][1]

Research

A 96-week phase II clinical study of adults with type 2 diabetes showed that bexagliflozin monotherapy provided a durable, clinically meaningful improvement of glycemic control, with a substantial reduction in weight and blood pressure, but no increase in the rate of significant adverse events.[5][6] In a clinical study of patients with type 2 diabetes and stage 3a/3b chronic kidney disease, bexagliflozin was well tolerated and shown to reduce hemoglobin A1c levels, body weight, systolic blood pressure and albuminuria.[7]

Veterinary uses

The data from two six-month field studies and an extended use field study demonstrated that bexagliflozin was over 80% effective in improving glycemic control in cats with diabetes mellitus.[3]

Bexagliflozin, sold under the brand name Bexacat, is an antidiabetic medication used to improve glycemic control in cats with diabetes.[3] Bexacat is the first sodium-glucose cotransporter 2 (SGLT2) inhibitor new animal drug approved by the US Food and Drug Administration (FDA) in any animal species.[3] It was approved for medical use in the United States in December 2022.[3][8] Bexacat is sponsored by Increvet Inc., based in Boston, Massachusetts.[3] Elanco licensed development and commercialization rights for bexagliflozin from Bexcafe, an affiliate of Increvet.[8]

References

Шаблон:Reflist

Further reading

Шаблон:Refbegin

Шаблон:Refend

Шаблон:Oral hypoglycemics and insulin analogs Шаблон:Sodium-glucose transporter modulators


Шаблон:Pharma-stub Шаблон:Vet-stub

Партнерские ресурсы
Криптовалюты
Магазины
Хостинг
Разное

  1. ↑ 1,0 1,1 Шаблон:Cite web Шаблон:PD-notice
  2. ↑ Ошибка цитирования Неверный тег <ref>; для сносок Bexacat FDA label не указан текст
  3. ↑ 3,0 3,1 3,2 3,3 3,4 3,5 Шаблон:Cite web Шаблон:PD-notice
  4. ↑ Ошибка цитирования Неверный тег <ref>; для сносок Brenzavvy FDA label не указан текст
  5. ↑ Шаблон:Cite journal
  6. ↑ Шаблон:Cite journal
  7. ↑ Шаблон:Cite journal
  8. ↑ 8,0 8,1 Шаблон:Cite press release
Источник — http://wikihandbk.com/ruwiki/index.php?title=Английская_Википедия:Bexagliflozin&oldid=13498690